SUBSCRIBE
SUBSCRIBE
News   Policy

Galenica Pharmaceuticals, Daiichi Sankyo, Inc. Drug Poses Risks, U.S. FDA Staff Says

January 31, 2008 | 
1 min read
Jan. 30 (Bloomberg) -- Daiichi Sankyo Co.'s drug Injectafer, which the company proposed selling for iron deficiency anemia, may pose ``serious safety concerns,'' U.S. regulators said.
Regulatory Europe
Daiichi Sankyo
MORE ON THIS TOPIC
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Approvals
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
July 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Killer Whale, orcinus orca, Adult Leaping, Canada
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
 · 
2 min read
 · 
Heather McKenzie
Approved and confirmed document file with check mark icon flat cartoon, concept of agreement or contract symbol with checkmark, accepted or certified license paper form pictogram isolated image
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Duchenne muscular dystrophy
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
July 1, 2026
 · 
2 min read
 · 
Tristan Manalac